Highlights second quarter 2025:
• Q2 revenue reached USD 55.3 million, a 12% increase year-over-year, with adjusted EBITDA of USD 13.6 million, up 41% from the prior year.
• Human Health Ingredients delivered USD 29.2 million in revenue, up 15% YoY, driven by continued volume growth and improved price mix. Adjusted EBITDA grew 28% to USD 13.9 million
• Consumer Health Products generated USD 27.1 million in revenue, an increase of 9% YoY, with stable gross margins and improved EBITDA margin due to good cost control
• Emerging Business reported USD 2.1 million in revenue, stable compared to previous quarters. EBITDA improved on lower opex following a reduction in marketing spend.
“We continued our positive momentum in the second quarter with double-digit revenue growth and a 41% increase in adjusted EBITDA. I am especially proud of the Human Health Ingredients segment, reaching an EBITDA of USD 13.9 million this quarter already. The expansion of our customer base — now larger and more diversified than ever — played a key role in this quarter’s performance.”, said Matts Johansen, CEO of Aker BioMarine.
Human Health Ingredients continued its strong performance with 15% revenue growth year-over-year, led by solid demand across all regions — particularly China and Asia Pacific. Adjusted EBITDA increased significantly, supported by improved volume, price, and lower unit costs.
Consumer Health Products delivered 9% revenue growth year-over-year. The growth was driven by continued momentum in Sam’s Club Multivitamin Gummies and Costco Taiwan. Gross margins remained stable, while EBITDA margins improved due to good cost control.
Outlook
The Human Health Ingredients segment sees continued year-over-year growth, supported by good underlying demand in multiple markets. In Consumer Health Products, the business has returned to modest growth, with revenues following market growth. The Emerging Business segment remains on track toward cash break-even, with active engagement in potential transactions. At the corporate level, the company has established a new, leaner cost base and is executing on initiatives to further improve financial and operational efficiency.
AKBM is adapting to market trends through productivity and cost measures while actively assessing the potential impact of increased macroeconomic uncertainty and new tariffs.
Get more information about our Q2 2025 report here
For further information, please contact
Christopher Robin Vinter, VP Strategic Finance & IR
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com